Psyched Wellness Receives DTC EligibilityCybin Advances IND-Enabling Studies of Two Psychedelic Molecules, CYB003 and CYB004 for Investigational New Drug ApplicaRritual Appoints Sarton Molnar-Fenton, Vice President Sales USATryp Therapeutics Announces Listing on OTCQB and DTC EligibilityPure Extracts Dual Vertical Approach Incorporating Cannabis and Psychedelic Compounds Is Starting To Pay OffTryp Therapeutics Appoints Greg McKee as Chief Executive OfficerPsyence Group and Pure Extracts Sign JV Letter of Intent for the Extraction of Psilocybin from Psychedelic Mushrooms andCybin Announces Senior Management Changes to Lead Buildout of Development and Clinical Capabilities in the United StatesPsyched Wellness Initiates Study on AME-1 Extract for Gut HealthRritual Superfoods to Launch Product Line in Rite Aid Stores – NationwideMushroomStocks.com Deep Dive: Tryp Therapeutics (CSE:TRYP)Cybin Signs Drug Development Agreement with Catalent for its Fast-Dissolve Formulation of Novel, Deuterated Tryptamine (Field Trip Has A Warchest Of Cash To Propel R&D and M&A Moving ForwardCybin Inc. Is Rapidly Progressing Its Drug Development Program With Plenty On The HorizonPure Extracts Orders Cutting Edge Vitalis Cosolvent Injection SystemTryp Therapeutics Announces Provisional Patent Filing For Improved Administration of PsychedelicsCybin Progresses Two Psychedelic Investigational New Drug (“IND”) Candidates and Announces Completion of Its 20th PrRritual Announces Successful Completion of Second Full Scale Manufacturing Run and Commencement of Third Full Scale ManuNuminus Wellness Is Taking Strides To Advance Its R&D Business UnitRritual Announces Successful Launch of US Facing E-Commerce Website and Provides Corporate Update
Back

Field Trip Health Has Its Sights Set On Jamaica To Spearhead Future R&D Initiatives

Feb 25, 2021 • 12:58 PM EST
2 MIN READ  •  By Michael Berger
Share Share - Facebook Share - Twitter

Field Trip Health Ltd. (CSE: FTRP) (OTCQX: FTRPF) is highly focused on the development and delivery of psychedelic therapies and is considered to be an industry leader.

In late 2020, Field Trip completed a go-public transaction on the Canadian Stock Exchange (CSE) and the market has responded favorably to the listing. So far this year, Field Trip has reported a number of major milestones and the stock has rallied more than 100%  as a result.

A few weeks ago, Field Trip had the official opening of the Field Trip Natural Products Limited Research and Development Laboratory for Psychedelic Fungi in Jamaica. The research facility is a state-of-the-art research and cultivation center that is dedicated exclusively to psilocybin-producing mushrooms and other plant-based psychedelics.

The facility is opening as part of Field Trip’s previously announced strategic partnership with the University of West Indies (UWI) and we are favorable on this aspect of the story. We believe that UWI provides Field Trip with important advantages and will monitor how the relationship advances from here.

With the opening of the facility, Field Trip and UWI have further enhanced its reputation as leaders in the research of psilocybin-producing fungi and how they can be efficiently utilized in a treatment setting. So far, we have seen positive clinical trial data reported by organizations like the Multidisciplinary Association for Psychedelic Studies (MAPS) and expect Field Trip to report important data points throughout the year.

The work at the new facility will leverage Field Trip’s research and development efforts and will be broad-ranging and will cover the vast majority of the 180+ recorded species of psilocybin-producing mushrooms. The company is highly focused on developing analytical methods for quality control, identification of novel molecules, as well as extractions and formulations for drug development purposes.

Field Trip has positioned itself as a global leader in the research and delivery of psychedelic-assisted psychotherapy and we are closely following the opportunity. Despite the recent rally, the company’s valuation is attractive when compared to some of its peers and we find this to be of significance.

If you are interested in learning more about Field Trip Health, please send an email to support@technical420.com with the subject “Field Trip Health” to be added to our distribution list.

Share Share - Facebook Share - Twitter

Tags

Authored By

Michael Berger

Comments

Get the Latest Cannabis News & Stock Picks.

Enter your email below to join the official Mushroomstocks newsletter.

 All good -- no spamming here.

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.
Subscribe
SUBSCRIBE NOW
close-link